Corporate

QPS Announces John Kolman as Executive Director and Head of Translational Medicine

(Newark, DE; November 24, 2014) – QPS Holdings, LLC, a leading full-service contract research organization, has named John Kolman, M.Phil., Ph.D. as Executive Director and Head of Translational Medicine. John Kolman will work with QPS’ Strategic Leadership Team to assist clients in quickly moving their drug candidates from pre-clinical through late stage development by employing diagnostic testing that allows the selection of appropriate and optimal drug therapies based on a patient's DNA, RNA, and/or protein pathophysiology.

“After many years of successful leadership by LingSing Chen, who recently retired after serving as Vice President and Global Head of Translational Medicine and Biosimilars, it is my pleasure to announce the hiring of John Kolman as her successor,” said Ben Chien, PhD, QPS President and CEO. “In his new position, John will be heading up our translational medicine division while serving our clients as an expert in biomarker research & development. As an effective business executive and innovative life scientist whose broad expertise includes all areas pertinent to translational and individualized medicine, John will be a major asset in this exciting and extremely important role, so crucial to our future success in helping clients develop personalized drug therapies.”

Kolman comes to QPS after over 20 years in the pharmaceutical R&D industry, having held multiple leadership roles. He is also well known throughout the industry for his scientific leadership, as evidenced by recent speaking engagements at fora such as the World PGx (Pharmacogenomics) Summit (San Francisco), the International Conference on Biomarkers and Clinical Research (Philadelphia), and the PDA/FDA (Parenteral Drug Association/Food and Drug Administration) Advanced Technologies for Virus Detection in Biologicals Conference (Bethesda). Kolman received his Ph.D. in Molecular Biophysics and Biochemistry from Yale University and his published works have appeared in such noteworthy periodicals as Science and Biologicals, and are pending with Applied Microbiology and Biotechnology, the Journal of Pharmaceutical Science and Technology, BioProcessing Journal, and in the PDA Press. His experience in biomarkers, biologics, pharmacogenomics, genetics, and bioinformatics has earned him recognition as an expert in these fields.

Download
back
top
20 years in pharma R&D navigation